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The relevance of solid form in drug development has been well established over time. In order to fully understand
drug properties, attention has been paid to solid state structure of drug molecules and their relationship to the
drug formulation. While each drug developer has had their own strategies and workflows for screening and
choosing solid forms of drug molecules, the industry is aware of instances where “the best laid plans” often go
awry. This manuscript has summarized several case studies in development programs that display the “good, bad,
and ugly” of solid form changes.
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It has been reported that the solid form of active
pharmaceutical ingredients (APIs) has significantly im-
pacted quality and consistency of the final dosage form
for drug development compounds (Newman and Byrn
2003), especially for solid oral dosage formulations.
Therefore, monitoring and controlling the API solid
form in both drug substance and drug product has been
recommended in order to ensure consistent biopharma-
ceutical properties throughout a drug development
program.
Every innovator drug developer has approached API
solid form decisions with a unique paradigm; however,
identifying and maintaining the optimal API solid form
in early pharmacokinetic studies, as well as maintaining
this form through product launch, has been recognized
as an ideal situation. This utopian scenario, however, has
often been noted to be far removed from reality, espe-
cially if the API solid form has been ignored or assumed
to be trivial for a particular program. This has often led
to significant program delays and cost as bioequivalence
studies, new crystallization studies, or formulation devel-
opment may have been needed.* Correspondence: ann.newman@seventhstreetdev.com
1Seventh Street Development Group, Kure Beach, NC 28449, USA
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the Creative Commons license, and indicate ifThis manuscript presents the “good, bad, and ugly” as-
pects of API solid form changes in the pharmaceutical
industry. It has explored and elaborated upon specific
case studies that outline the impact of API solid form
changes brought about by choosing a non-ideal salt form
for early preclinical development, relaxed due-diligence
for a “fast-tracked” compound, a serendipitous late stage
form change, lack of attention to solid form for an in-
licensed compound, and a less than bullet-proof intellec-
tual property (IP) landscape surrounding an innovator
molecule.
The goal of these examples was to show that adequate
attention to API solid form during development will aid
in managing risk for a program. Whether an innovator
company was looking to out-license a gold molecule as a
platinum package, an innovator company was looking to
bring a drug to market with a strong patent landscape,
or a generic company was looking to enter the market
with IP for their molecule, the case studies presented in
this manuscript clearly show that API solid form is an
important aspect of any development program.
The case studies presented, in addition to many other
un-published examples, have confirmed to pharmaceut-
ical scientists that no screening strategy can guarantee
that all crystal forms have been discovered. However, ap-
propriate attention to API form and a sound screeningThis article is distributed under the terms of the Creative Commons Attribution
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Classification of crystalline API forms. The red box signifies that polymorphs of all solid form classes are possible; the blue boxes represent
classes containing hydrates
Fig. 2 Structure of indinavir
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form changes in the API and drug product.
Solid forms have been defined as both crystalline and
amorphous materials in this paper. Crystalline forms
have been sub-classified into categories outlined in Fig. 1,
and described as neutral (such as free forms and co-
crystals) and charged (salts or salts of co-crystals) species.
Each category of crystalline materials has the possibility
of displaying polymorphism (solvates and hydrates have
been included in our polymorph classification based on
the regulatory definition). Any material from the crys-
talline API categories that lacks long range order as
characterized by x-ray powder diffraction (XRPD) has
been referred to as amorphous API.
Case studies
Indinavir - early salt form change
Indinavir sulfate, marketed as Crixivan® (Fig. 2), was
approved in 1996 as a human immunodeficiency virus
type 1 (HIV-1) protease inhibitor indicated for treat-
ment of HIV infection and AIDS in adults (Lin 1999;
Lin et al. 1998; Crixivan Package Insert. (available at
http://www.merck.com/product/usa/pi_circulars/c/crixi
van/crixivan_pi.pdf. Accessed 23 Feb 2016). Crixivan®
was initially developed as a free base monohydrate,
but suffered from significant pH dependent solubility
(Fig. 3) and limited adsorption as the free base form
(Lin et al. 1998). As a result, a need to identify an ac-
ceptable, soluble salt for clinical dosage development
arose for researchers. The pH solubility profile and
pKa of the molecule suggested a rather acidic salt
was necessary to achieve complete dissolution. One
issue, however, was that Crixivan® was quite unstable
in acidic solutions (Table 1), which presented astability risk for solid salt forms (Lin et al. 1998). The
crystalline sulfate salt ethanolate was chosen as the
lead salt form for development. The aqueous solubil-
ity for this salt form was in excess of 500 mg/ml with
a resulting solution pH of < 3. The main concern for
the sulfate salt ethanolate was the excessive hygro-
scopicity (Fig. 4). Additionally, the ethanolate had the
potential to change physical form at elevated humid-
ity, even potentially going amorphous. Because of this,
extensive solid-state stability and excipient compatibil-
ity studies were performed using controlled humidity
conditions. Experiments showed that a shelf life of >
2 years was possible when the humidity was kept <
30 % relative humidity (RH), even for the amorphous
sulfate salt. At temperatures and humidity above 40 °
C and 30 % RH respectively, the sulfate salt suffered
from rapid degradation for both the API and drug
product. Because of the need for low RH, a dry
granulation formulation process was developed for
the drug product (Lui et al. 2003). Human clinical trials
were conducted with both the sulfate salt ethanolate
Fig. 3 pH solubility profile of indinavir (adapted from Ref (Lin
et al. 1998))
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showed that the sulfate salt in the fasted state or with a
low fat meal yielded the highest exposures (Fig. 5).
This example has clearly displayed the utility of identi-
fying the appropriate salt form before clinical trials have
been initiated and has also represented a “good” scenario
for solid form in development. This case study has pre-
sented a classic example of solid state form impacting
pharmacokinetic profiles of a drug. The example has
also shown that relatively poor physicochemical proper-
ties can be mitigated with a thorough understanding of
both chemical and physical stability profiles. The sulfate
salt ethanolate displayed excessive hygroscopicity and
form change potential; however, processing and storage
conditions were identified to successfully process and
store API and drug product.
DPC 961 – Form change on a fast track compound
DPC 961 (Fig. 6) was a development compound indi-
cated for the treatment of HIV infections and was devel-
oped as a neutral molecule (Staszewski et al. 1999). The
compound was designated as Biopharmaceutics Classifi-
cation System (BCS) II, with high permeability, low
aqueous solubility and therefore would display dissol-
ution limited behavior (Aungst et al. 2002). As a result,Table 1 pH Stability Data for Indinavir (used with permission from R
product/usa/pi_circulars/c/crixivan/crixivan_pi.pdf. Accessed 2 Marc
pH Buffer
1 0.1 M HCl
2 0.1 M maleate
3 0.1 M citrate
4 0.1 M citrate
5 0.1 M citrate
11 0.1 M carbonate (1/1 MeOH/H2O)physicochemical characteristics such as particle size,
crystal form, and surface area may have had a direct im-
pact on bio-performance. Early in development, this
compound had been known to exist in many solvated
forms in addition to a single, anhydrous crystal form
(Form I) (Desikan et al. 2005). Preliminary screening
work had never identified crystallization solvents that
directly isolated Form I. All pathways to Form I involved
forming a solvate and then de-solvating to obtain Form
I. The first 29 development batches of DPC 961 involved
isolation of the API through crystallization from tolu-
ene/heptane, followed by re-crystallization from metha-
nol (MeOH). Anhydrous Form I was the product in all
29 batches; however, this form was not directly crystal-
lized, but instead, formed through de-solvation of the
stoichiometric MeOH solvate by elevated temperature
drying. On the 30th batch, a lower melting crystal form,
anhydrous Form III, was the product. Form III was de-
termined to be enantiotropically related to Form I, with
Form III being the low temperature stable polymorph
with transition temperature between 120 and 174 °C, as
determined from DSC data using Burger’s rules. A van’t
Hoff investigation had not been performed in this
polymorph system, presumably since no solvent had
been found that had not formed a solvate with either
Form I or III.
After the serendipitous discovery of Form III, Form I
was never again manufactured at large scale. When the
desolvation employed in the first 29 batches was
attempted after Form III was discovered, the product
was now Form III, and not Form I. Form I had been pre-
pared on small scale by heating Form III above melting
point, but a manufacturing process could not be devel-
oped. This circumstance was a clear example of the
phenomenon labeled as a “disappearing polymorph”
(Dunitz and Bernstein 1995). Due to this change in
form, researchers were now left with Form III. Since the
compound was BCS II, dissolution may have critically
impacted bioperformance. Thus, the first set of experi-
ments necessary when Form III was discovered and real-
ized to be the future chosen phase was to understand
bio-relevant dissolution and solubility. Fortunately, Form
III had comparable aqueous solubility and intrinsicef (Crixivan Package Insert. (available at http://www.merck.com/
h 2015))
k1 (hr
−1) at 40 °C t1/2 (days) at 40 °C
2.16 × 10−3 13
1.14 × 10−3 25
7.12 × 10−4 41
3.36 × 10−4 86
1.10 × 10−4 262
1.23 × 10−3 23
Fig. 4 Water sorption/desorption profile of indinavir (adapted from
Ref (Lin et al. 1998))
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was necessary to confirm that bio-performance would
not be impacted by the crystal form change. When Form
I and Form III were formulated into tablets and orally
administered to dogs at 100mpk, the oral absorption
profiles were statistically identical (Fig. 7). If this had not
been the case, and formulated Form I resulted in a
unique absorption profile compared to Form III, aFig. 5 AUC (a) and Cmax (b) curves for indinavir as a function of the admi
dose. ○ sulfate salt fasted state; ● sulfate salt following a high-fat meal;☆
free base capsules following a high-fat meal; ♦ free base oral suspension fahuman bridging study would have been necessary. The
cost and program delays would have been substantial.
While statistics are not available, the chances of Form
III and Form I having identical bio-performance for a
BCS II compound was likely to be low. The more prob-
able result would have been distinct solubility and/or
dissolution differences between the polymorphs. Even
though a clinical bridging study was not necessary after
the polymorph change, the research team still had to de-
velop a unique API isolation process and update analyt-
ical methods, in addition to providing the necessary data
to prove polymorph stability and bio-equivalence, which
would have likely taken a minimum of six months to
perform.
The lessons learned from this case study would vary
based on the company’s risk-management strategy. It
has been generally accepted that isolating the final crys-
tal form through desolvation would be a non-ideal
process; rather, a process where the final form has been
directly nucleated and grown (with or without seeds)
would be preferred. However, there have been com-
pounds that, when developed initially, have only ap-
peared to form solvates. These solvates may or may not
have had the potential to de-solvate to a physically stable
anhydrous crystal form. In this case study, Form Inistered single-dose; AUC and Cmax values were normalized to a 1-mg
sulfate salt following low fat meal; □ free-base capsules fasted state; ▪
sted state (used with permission from Ref (Yeh et al. 1998))
Fig. 6 Structure of DPC 961
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not found to be an anhydrous crystal form that could
have been directly nucleated and grown in an appropri-
ate solvent system. Due to the speed of the program, it
could have easily been argued that the process was ro-
bust in isolating Form I, as 29 batches had been com-
pleted without incident. The opportune discovery of
Form III may have occurred due to a variety of causes
including, but not limited to: impurity differences (either
level or actual type of impurities) in the process stream,
unique levels of supersaturation, or foreign particle pro-
viding heteronuclear templates for nucleation. It is not
known whether extensive screening early in the program
would have uncovered Form III. However, many com-
pounds that have only been isolated as a solvate hadFig. 7 Comparison of DPC 961 oral absorption in dogs administered
100 mg tablet formulations prepared with polymorph form I (○) or
form III (■). (used with permission from Ref (Aungst et al. 2002))often times masked an anhydrous crystal form that had
been anticipating the right trigger in order to be discov-
ered. Therefore, an appropriate and diligent level of
crystal form screening should be applied to this type of
compound, especially since the compound was desig-
nated at BCS II. The screening strategy should have in-
volved conditions attempting to avoid solvate formation
(Campeta et al. 2010). This “fast-track” compound could
be deemed a “bad” scenario when the time delays and
increased costs to the project have been added to the de-
velopment plan.
Atorvastatin - crystalline form change in late
development
Atorvastatin (CI-981) is an HMG CoA reductase inhibi-
tor marketed as Lipitor® (Fig. 8). As a BCS II drug, it has
exhibited poor solubility and high permeability (Wu and
Benet 2005). The compound was originally discovered at
Warner-Lambert in the 1980’s, and the amorphous form
of the hemi calcium salt pure enantiomer was used for
early clinical trials. Phase 1 studies were conducted by
the Parke-Davis Clinical Research Unit (CRU) recruiting
twenty-four (24) males from within the company (Lie
2009). Phase 2 clinical trials showed an improvement in
performance when compared to data from four mar-
keted drugs (Fig. 9). Priority review status was requested
in 1994, but was denied because the drug had not met an
unmet medical need. The company proceeded to fund a
clinical study for familial hypercholesterolemia, where the
compound showed efficacy, and they were granted priority
review status which helped to shorten the development
time. Atorvastatin calcium was approved by the Food and
Drug Administration (FDA) in late 1996.
The only known solid form for atorvastatin calcium in
Phase 1 and 2 clinical trials was the amorphous form. It
exhibited poor filtration and drying characteristics for
large scale batches and required protection from heat,
light, oxygen, and moisture (Briggs et al. 1999). During
Phase 3 clinical trials, a crystalline form was produced
at scale which was determined to be a trihydrate and
referred to as Form I (Briggs et al. 1999). This crystal-
line form possessed a number of advantages over the
amorphous form including higher purity, improvedFig. 8 Structure of atorvastatin
Fig. 9 Atorvastatin (CI-981) Phase II results compared with marketed products (adapted from Ref (Lie 2009))
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distribution, and better filtration and drying properties.
While finding a new form at this stage of development
would normally be undesirable, the improvements
gained with the new crystalline form were substantial
enough for researchers to change the solid form during
late development. All aspects of the project needed to
be repeated, such as the API manufacturing process
development, formulation development, stability stud-
ies, analytical methods, and human bioequivalence test-
ing. Tablets produced with amorphous and crystalline
trihydrate atorvastatin calcium showed a difference in
the rate of absorption, but equivalent extent of absorp-
tion in the bioequivalence test (Pfizer Citizen Petition.
Docket no 2005P).
Other crystalline forms were patented along with
Form I (designated Forms II and IV) (Briggs et al. 1999),
and additional forms followed in subsequent patent ap-
plications (Byrn et al. 2003; Tesslor et al. 2003; Van Der
Schaaf et al. 2009). The next challenge for the team was
to develop a crystallization process that produced
uniquely Form I with the desired characteristics they
needed. One patented process reported that adding
methyl-t butyl ether (MTBE) to the reaction mixture
after forming the salt, followed by subsequent seeding,
had produced the desired Form I (Tully 2003).
The FDA orange book has listed a number of patents
for atorvastatin calcium, including the composition of
matter patent (expired September 24, 2009), a salt patentincluding the calcium salt (expired Dec 28, 2010), and
the crystalline Form I patent (expires July 8, 2016). By
using a form other than Form I, generic products were
technically allowed on the market in 2010. After numer-
ous legal battles and an agreement between Pfizer and
Ranbaxy, the generic version of Lipitor® was available in
late 2011 (Lie 2009).
The atorvastatin story has covered a number of teach-
ing points regarding solid forms. Polymorph screens
were not routinely performed when atorvastatin was
under development and it was common to find forms
during scale-up, especially when conditions were chan-
ged. In the case of atorvastatin, a screen was performed
after the crystalline form was found and a number of
forms were produced, based on the patent literature
(Briggs et al. 1999; Byrn et al. 2003; Tesslor et al. 2003;
Van Der Schaaf et al. 2009). In present day cases, a solid
form screen should be performed in early development
to find a suitable form long before Phase 3 clinical trials.
An earlier solid form screen would also have prevented
the repeat of major studies late in development, as seen
when atorvastatin Form I was found. Screening studies
do not guarantee that all forms have been found, but
they have significantly reduced the risk for most pro-
grams. The patents listed in the Orange Book and the
strategy of using patents to maintain market share
have also been recognized as an important lesson from
this example since it has necessitated consideration of
a patent strategy whenever new forms (polymorphs,
Fig. 10 Structure of gatifloxacin
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dispersions, etc.) have been found during development.
While the initial discovery of a crystalline form during
Phase 3 clinical trials would have normally been consid-
ered a “bad” scenario, the atorvastatin story has proven
that after the extra work has been completed, a very
“good” scenario and a successful product resulted.
Gatifloxacin - crystalline form changes with a licensed
compound
Gatifloxacin (also known as AM-1155, CG5501, and
BMS-206584) has been established as a fluoroquinolineFig. 11 Gatifloxacin crystalline forms from ethanaol, water, and various drybroad-spectrum antibiotic (Fukuda et al. 1998) (Fig. 10).
It was originally discovered by Kyorin Pharmaceuticals
in the late 1980s as a hemihydrate that was recrystallized
from methanol (Masuzawa et al. 1991). This crystalline
form was found to be hygroscopic and resulted in poor
tablet disintegration and dissolution. In the mid-1990s, a
sesquihydrate was found by Kyorin with improved prop-
erties (Matsumoto et al. 1999). The compound was li-
censed to Bristol-Myers Squibb (BMS) in 1996 with two
hydrated forms disclosed.
Initial clinical formulations at BMS utilized the sesqui-
hydrate in a wet granulation process. The clinical batch
failed specifications when a new crystal form was discov-
ered in the batch. The new crystal form was confirmed
as a pentahydrate (Raghaven et al. 2002), which was
found to be less soluble and more stable in various for-
mulations (wet granulations, dry blends, and aqueous
suspensions). Issues with the initial clinical sesquihydrate
formulation, as well as difficulty producing pure sesqui-
hydrate material, had prompted crystallization studies to
find a better understanding of the solid form landscape.
Crystallization studies using only ethanol, water, and
various drying conditions resulted in 12 additional forms
for gatifloxacin (Fig. 11) (Raghaven et al. 2002). These
studies added considerable elements to the development
timeline of the compound, including finding the forms,
developing API processes for the desired forms, optimiz-
ing clinical formulations, and requalifying analyticaling conditions (adapted from reference (Raghaven et al. 2002))
Fig. 12 Structure of olanzapine
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ical properties for the API and formulation, it was also
found to be less bioavailable compared to the sesquihy-
drate. This resulted in a switch back to the sesquihydrate
form for the marketed tablet formulation Tequin®, ap-
proved in 1999 (Fish and North 2001). Potentially fatal
blood sugar problems resulted in a blackbox warning for
Tequin®, as well as a subsequent removal of Tequin®
from the US and Canadian markets in 2006. The ses-
quihydrate was subsequently used in the production of
ophthalmic solutions, Zymar® and Zymaxid®. After the
compound patent had expired in 2010, Apotex started
to use the hemihydrate in their generic product.
Gatifloxacin has provided an example of multiple form
changes throughout mid to late stage development. These
changes created significant additional work around API
crystallization development, formulation processing, ana-
lytical methods, and biological studies (i.e., bridging and
bioequivalence studies). This case study has also demon-
strated the criticality of due diligence for in-licensed
compounds, including proper screening. Companies
that in-license a compound should ask specific ques-
tions about the solid form studies that were performed to
determine the scope of knowledge and inter-relationships
between forms, and how the solid form landscape would
impact the desired dosage form and development plan.
For companies that out-license a compound, a solid form
study targeted toward the most stable form, crystallization
conditions, and formulation processes have resulted in a
much stronger package.
While the initial package for gatifloxacin seemed
straightforward with only two hydrated forms, it should
be classified as an “ugly” scenario due to the solid form
changes and additional studies.Lifecycle management
Olanzapine - crystalline change from free acid to salt
Olanzapine (Fig. 12), a Biopharmaceutics Drug Dispos-
ition Classification System (BDDCS) 2 drug (Benet et al.
2011) with poor solubility and high permeability, has been
marketed towards treating schizophrenia. Olanzapine has
been shown to exhibit a number of different crystalline
forms including hydrates (Reutzel-Edens et al. 2003)
and solvates (Cavallari et al. 2013). Form I has been
deemed the most stable unsolvated form (Reutzel-Edens
et al. 2003). A variety of dosage forms have been devel-
oped to target different patient populations. These prod-
ucts have included Zyprexa® tablets (once a day oral
tablets), Zyprexa Zydis® orally disintegrating tablets (that
can be taken without water), and Zyprexa Intra Muscular®
(rapid acting intramuscular injection). A combination cap-
sule product with fluoxetine hydrochloride (HCl) (Sym-
byax®) was also launched when indications were expandedto include treatments of bipolar disorder and resistance
depression in its marketing.
A major issue with this patient group was compliance;
as a result, a dosage form that lasted longer than once
daily would have provided a significant benefit for the
patients. To address this issue, researchers developed a
long acting injection (LAI) using olanzapine pamoate
monohydrate and sold as Zyprexa Relprevv® in 2010
(Chue and Chue 2012). The pamoate salt was shown to
be poorly soluble in aqueous media, and micron sized
crystals were suspended in a diluent containing car-
boxymethylcellulose sodium, mannitol, polysorbate 80,
sodium hydroxide and/or hydrochloric acid for pH ad-
justment and water for injection (Zyprexa Relprevv
Package Insert 2014). As a result, the salt slowly dis-
solved after injection into the muscle, resulting in an
absorption of olanzapine systemically over a period of
several weeks (Citrome 2009). The half-life of the
pamoate salt became 30 days, in comparison to 33 h for
an oral dose (Di Lorenzo and Brogli 2010). One injec-
tion has been noted to last three to four weeks, provid-
ing better efficacy and compliance for patients (Fig. 13)
(Agency et al. 2015). The efficacy and tolerability pro-
files for the LAI were found to be the same as the oral
formulation. The olanzapine Form II patent listed in
the Orange Book (US 6960577) is set to expire in 2017.
The olanzapine pamoate monohydrate patent listed in
the Orange Book (US 6169084) has an expiry date of
2018, which has given the LAI dosage form a year of
extra patent coverage.
This case study has illustrated the advantages of using
novel solid forms for innovative drug products. The
change in solid form to a crystalline pamoate salt re-
sulted in a less soluble salt, which has previously not
been desired by researchers. However, in this case, the
less soluble salt exhibited all the properties needed for
Fig. 13 Mean olanzapine plasma concentrations for the Multiple-Dose Group receiving 405 mg/4 weeks; arrows along x-axis indicate injections
(adapted from reference (Agency et al. 2015))
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an oral dosage form, an intramuscular injection was pro-
duced to capitalize on the lower solubility. The result be-
came a dosage form with good efficacy and superior
compliance. Additionally, patent coverage around the
new salt has also extended coverage for a year after the
olanzapine free base expires.Fig. 14 Structure of oxybutynin HClOxybutynin- crystalline change from salt to free base
Oxybutynin HCl (Fig. 14) has been recognized as a
BDDCS I compound exhibiting high solubility and per-
meability (Benet et al. 2011). It has been used in a var-
iety of marketed products for the treatment of overactive
bladder (Gamble and Sand 2008). The first oral formu-
lation from Hoechst Marion Roussel in 1975 was an
immediate release tablet (Ditropan®), which was dosed
three times a day. The major side effect was dry mouth,
which was the primary reason for patients discontinu-
ing use (Sathyan et al. 2001). The side effect of dry
mouth was caused by the metabolite desethyloxybuty-
nin. The metabolite was reduced by developing a con-
trolled release dosage form, which maintained a zero
order release. This resulted in lower peak to trough var-
iations in plasma levels and bypassed the pre-systemic
metabolism and conversion to the active metabolite.
Ditropan XL® was launched in 1999 using Alza’s os-
motic delivery (OROS) formulation approach, which re-
duced the severity of dry mouth side effects (Sathyan
et al. 2001). This formulation approach also allowed
one daily dose, as opposed to the original three daily
doses, which was more convenient for the patient and
helped improve patient compliance.Another way to reduce the metabolite and side effects
was to bypass the first pass metabolism using a differ-
ent administration route. Watson launched an Oxytrol®
transdermal patch in 2003, which was designed to de-
liver oxybutynin over a three to four day interval. Re-
formulation into the patch required researchers to use
the oxybutynin free base, instead of the hydrochloride
salt, for better skin transport. Bypassing the oral deliv-
ery route significantly reduced the metabolite (Fig. 15),
which resulted in minimal side effects and better pa-
tient compliance (Gamble and Sand 2008). In January
2013, an over-the-counter (OTC) patch was approved
by the FDA for commercial use (http://www.fda.gov/
NewsEvents/Newsroom/PressAnnouncements/ucm336
815.htm. Accessed 2 March 2015).
This case study shows how a change in form and de-
livery route has not only reduced side effects, but also
resulted in a more efficient and convenient drug product
for the patient. The development of the patch required a
change in form from the hydrochloride salt to free
base, which enabled the drug to pass through the
skin. Finding a different form to develop an improved
Fig. 15 Comparison of blood levels of oxybutynin and its metabolite, N-desethyloxybutynin, showing that the patch resulted in significantly lower
levels of the metabolite, which reduced the dry mouth side effect, compared to the oral immediate release formulation (Oxytrol Package Insert.
(available at http://pi.watson.com/data_stream.asp?product_group=1295&p=pi&language=E. Accessed 2 March 2015)
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erties needed for a particular dosage form and thor-
ough characterization of various forms. This change in
form could include a polymorph, free acid/base, salt,
cocrystal, or amorphous solid dispersion. Specific counter-
ions or guest molecules would need to be considered for
certain delivery routes, such as dermal, ophthalmic, intra-
venous, or intramuscular formulations (Paulekuhn et al.
2007). Determining the issues with current products and
finding creative solutions using form and formulation to
produce an improved product has been recognized as a
true “win-win” in lifecycle management.Conclusions
The case studies in this manuscript have been presented
to show why it has been critical to characterize, under-
stand, and monitor the solid form in all stages of drug
discovery and development. While these case studies
have been presented in the literature, there have been
even “uglier” cases that have not been published. It is
important for researchers to realize that form selection
is not a unit operation, but an integral part of the entire
drug development process, with no clear beginning or
end; instead, there should be continuous scrutiny and
monitoring as a candidate progresses from discovery to
development to market and beyond.
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